PETER HARPER, Guy’s Hospital, London REFERENCE: “Management of Tumour and Treatment Related Symptoms” section, Perspectives in Lung Cancer, Seville Bisphosphonates may be more suited
PETER HARPER, Guy’s Hospital, London
REFERENCE: “Management of Tumour and Treatment Related Symptoms” section, Perspectives in Lung Cancer, Seville
Bisphosphonates may be more suited for improving the outlook among patients with lung cancer who have bone metastases compared to palliative radiation and analgesics, according to Peter Harper, who assessed the data from recent studies for delegates at the Lung Cancer conference in Seville. He talked with Peter Goodwin.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.
Tags
Related Episodes
Jonathan W. Goldman MD and David R Spigel MD; ASCO 2026: Patients with RET Fusion Positive Early Stage Non-Small Cell Lung Cancer Benefit from Selpercatinib: LIBRETTO-432 Early Results
Patients with RET Fusion Positive Early Stage Non-Small Cell Lung Cancer Benefit from Selpercatinib: LIBRETTO-432 Early Results An interview with: Jonathan W. Goldman MD, Director of Clinical Trials i
Eileen M O'Reilly MD; ASCO 2026: RAS G12 Targeting Drug Daraxonrasib Doubles Survival with Pancreas Cancer in Phase 3 RASolute 302 Study
Standing ovation at ASCO for RASolute 302 Study
Rukhmini Bandyopadhyay MD, AACR 2026: AI “Pathomics Platform” Selects Immunotherapy, Predicts Outcome for Patients with Metastatic Non-Small Cell Lung Cancer
AI “Pathomics Platform” Selects Immunotherapy, Predicts Outcome for Patients with Metastatic Non-Small Cell Lung Cancer An interview with: Rukhmini Bandyopadhyay MD, Postdoctoral Fellow, The Universi